Clinical Trials Browser

Ovarian Neoplasms

NCT03906669 2023-11-22

WinPro

Phase 2 Unknown

200 enrolled

Breast

Breast Neoplasms

NCT05800756 2023-04-06

Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer

Phase 2 Unknown

30 enrolled

Breast

Breast Neoplasms

NCT04942899 2023-03-01

Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer

Phase 2 Unknown

70 enrolled

Breast

Breast Neoplasms

NCT05411380 2022-11-04

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Phase 2 Unknown

73 enrolled

Breast

Breast Neoplasms

NCT05512416 2022-08-23

Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

Phase 2 Unknown

35 enrolled

Breast

Breast Neoplasms

NCT05512780 2022-08-23

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

Phase 2 Unknown

30 enrolled

Other solid neoplasm

Solid Tumor

NCT03633331 2021-10-15

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Phase 2 Unknown

93 enrolled 8 charts

Breast

Estrogen Receptor-positive Breast Cancer

NCT04407988 2021-10-13

Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer

Phase 2 Unknown

86 enrolled

Breast

Breast Neoplasms

NCT04571437 2020-10-01

B-001

Phase 2 Unknown

204 enrolled

Breast

Breast Neoplasms

NCT04095390 2019-09-19

INPHASE

Phase 2 Unknown

60 enrolled

Breast

Breast Neoplasms

NCT04088110 2019-09-12

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Phase 2 Unknown

77 enrolled

Breast

Breast Diseases, Breast Neoplasms

NCT03024580 2019-08-15

MEGA

Phase 2 Unknown

20 enrolled

Breast

Breast Neoplasms

NCT04023292 2019-07-17

Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

Phase 2 Unknown

185 enrolled

Breast

Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

Phase 2 Unknown

250 enrolled

Breast

Breast Diseases, Breast Neoplasms

NCT02689921 2018-09-28

NEOADAPT

Phase 2 Unknown

7 enrolled

Breast

Breast Neoplasms

NCT03497702 2018-04-13

NeoChAI

Phase 2 Unknown

114 enrolled

Breast

Breast Neoplasms

NCT02214004 2018-02-15

HERAKLES

Phase 2 Unknown

132 enrolled

Breast

Breast Neoplasms

NCT02910050 2017-12-22

BETTER

Phase 2 Unknown

58 enrolled

Breast

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02551367 2015-09-16

LVCCFOROI

Phase 2 Unknown

110 enrolled

Anovulation, Polycystic Ovary Syndrome

NCT02482740 2015-06-26

TGOG1005

Phase 2 Unknown

44 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT02188550 2015-05-19

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

Phase 2 Unknown

20 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT02313051 2014-12-09

MIRACLE

Phase 2 Unknown

200 enrolled

Breast

Breast Neoplasms

NCT01709370 2013-12-31

Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women

Phase 2 Unknown

45 enrolled

Breast

ER Positive, HER2 Negative Breast Cancer

NCT01924078 2013-08-16

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

Phase 2 Unknown

100 enrolled

Breast

Breast Neoplasms

NCT00687648 2009-06-17

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 2 Unknown

70 enrolled

Breast

Breast Neoplasms

NCT00280930 2007-01-19

Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer

Phase 2 Unknown

60 enrolled

Breast

Breast Neoplasms

Clinical Trials

Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors

WinPro

Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer

Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer

B-001

INPHASE

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

MEGA

Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

Pyrotinib

NEOADAPT

NeoChAI

HERAKLES

BETTER

LVCCFOROI

TGOG1005

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

MIRACLE

Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer